Faeth Therapeutics Stock Price, News & Analysis
Company Description
Faeth Therapeutics (NASDAQ: FTH) is a publicly traded company. The company has a market capitalization of $23.9M, ranking #6,180 among all listed U.S. companies by market cap.
FTH stock has gained 22.6% over the past year. Shares last traded at $18.07.
On a trailing twelve-month basis, Faeth Therapeutics reported net income of -$21.1M and diluted earnings per share of $-16.72.
This page provides a comprehensive overview of FTH stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Faeth Therapeutics (FTH) stock last traded at $18.07. Over the past 12 months, the stock has gained 22.6%. At a market capitalization of $23.9M, FTH is classified as a micro-cap stock with approximately 1.3M shares outstanding.
FTH Rankings
Latest News
Faeth Therapeutics has 1 recent news article, with the latest published 6 days ago. View all FTH news →
SEC Filings
Financial Highlights
operating income reached -$22.3M, and net income was -$21.1M. Diluted earnings per share stood at $-16.72. The company generated -$20.5M in operating cash flow. With a current ratio of 5.06, the balance sheet reflects a strong liquidity position.
Upcoming Events
Topline Phase 2 readout
Interim Phase 1b/2 readout
Faeth Therapeutics has 2 upcoming scheduled events. The next event, "Topline Phase 2 readout", is scheduled for July 1, 2026 (in 9 days). Investors can track these dates to stay informed about potential catalysts that may affect the FTH stock price.